Abstract: Despite improved surgical techniques, relapse and mortality rates remain high among patients with resected non-small cell lung cancer. Numerous randomized controlled trials in the 1980s and 1990s were unable to demonstrate a consistent survival benefit for adjuvant chemotherapy. However, in the past 2 years, the results of three pivotal trials have unequivocally shown the benefit to adjuvant treatment in resected non-small cell lung cancer. In this review, we describe early adjuvant trials and highlight the recent landmark studies in this disease. The focus of ongoing and future research efforts is also discussed.
L ung cancer is the leading cause of cancer mortality in the western world and accounts for more deaths than breast, colon, and prostate cancers combined. 1 Surgical resection remains the treatment of choice for early-stage non-small cell lung cancer (NSCLC), yet 5-year survival rates for stage I and II disease are only 60 to 70% and 35 to 40%, respectively. 2 Recurrences tend to occur at extrathoracic sites, suggesting the presence of micrometastatic disease at the time of surgery. These observations led to the hypothesis that adjuvant systemic therapy should improve outcomes in resected NSCLC. However, it has taken almost 3 decades of clinical research to prove this hypothesis correct.
Early efforts to improve the outcome of resected NSCLC involved the use of postoperative radiotherapy. However, a meta-analysis published in 1998 involving nine randomized controlled trials (RCTs) suggested a detrimental effect of postoperative radiotherapy in NSCLC. Radiotherapy was associated with a 21% relative increase in risk of death, which translated to an absolute decrease of 7% in 2-year overall survival (reducing survival from 55% to 48%). 3 Platinum-based chemotherapy regimens, the standard of care for the first-line treatment of advanced NSCLC, have been tested against observation in the adjuvant setting in North America and Europe since the 1970s. Investigators in Japan, however, have largely studied milder oral regimens involving tegafur (an oral 5-fluorouracil derivative) plus uracil (UFT). Despite numerous trials, until 2004, most authorities felt there was insufficient evidence to recommend the use of adjuvant chemotherapy for resected NSCLC. However in the last 2 years, the results of three pivotal clinical trials have led to a major change in practice patterns, with most oncologists now strongly recommending adjuvant systemic therapy in good performance status patients with resected NSCLC. 4 -6 In this review, we describe early RCTs of adjuvant chemotherapy for completely resected NSCLC (limited to trials with Ͼ100 patients) of both platinum-based and oral adjuvant chemotherapy. Emphasis is on the recently completed landmark studies. The focus of ongoing and future research efforts in this field is also discussed.
PLATINUM-BASED CHEMOTHERAPY

Studies Conducted before 1990
Several clinical trials in the 1970s and 1980s evaluated the role of adjuvant cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy in resected NSCLC (Table 1) . Results from two of these trials suggested a possible benefit from adjuvant chemotherapy, but the differences were not statistically significant. 7, 8 The Lung Cancer Study Group trial 772 randomized 141 patients with completely resected stage II and III NSCLC to receive six cycles of CAP chemotherapy or bacillus Calmette-Guerin and levamisole immunotherapy. 7 Both median survival (23 versus 16 months) and overall survival at 2 years (41% versus 30%) showed non-significant trends in favor of CAP chemotherapy. In the subsequent LCSG 801 trial, Feld et al. 9 randomized 283 patients with stage IB and II NSCLC to four cycles of CAP chemotherapy or observation. Among the 269 eligible patients, no statistically significant survival difference was observed after a mean follow-up of 3.8 years.
A Finnish trial of adjuvant CAP chemotherapy that was limited to patients without nodal involvement by tumor (T1-3N0) was the second study to suggest that adjuvant chemotherapy conferred a survival advantage in resected NSCLC. Despite the small size of this trial (only 110 patients), a survival advantage of borderline significance was seen in favor of chemotherapy (P ϭ 0.05). Patients with T2 tumors seemed to derive the greatest benefit from chemotherapy, although the confidence of this observation is limited by the small number of patients in the subset. 8 However, given the lack of a convincing survival benefit from CAP in any of these adjuvant trials, its use was largely restricted to the research setting.
REGIMENS CONTAINING SECOND-GENERATION VINCA ALKALOIDS AND EPIPODOPHYLLOTOXINS
In the 1990s, emphasis shifted from alkylating agents to the use of platinum-based regimens using the vinca alkaloids vinblastine and vindesine (Table 1) . Two small trials evaluating the combination of vindesine/cisplatin failed to show a survival benefit versus postoperative observation alone. 10, 11 The large multicenter Adjuvant Lung Project Italy (ALPI) trial randomized 1196 patients to receive three cycles of adjuvant mitomycin, vindesine, and cisplatin chemotherapy or observation alone. 12 Radiotherapy was permitted according to each center's existing treatment policy, and its use was equal in both treatment groups (43%). After a median follow-up of 64.5 months, no statistically significant differences in overall or progression-free survival were detected between treatment groups, nor was survival by treatment group affected by disease stage. A recently published study by Park et al. 13 also failed to find a significant survival benefit for postoperative mitomycin C, vinblastine, and cisplatin. This randomized study of 118 patients with completely resected stage I NSCLC (82% stage IB) had a mean follow-up of 7.3 years. Although there was a significant improvement in disease-free survival for the chemotherapy group, the 5-and 10-year overall survival rates of 74.6% and 56.3% in the control group and 81.4% and 65.0% in the chemotherapy group, respectively, were not significantly different (P ϭ 0.19). The lack of statistical significance may be the result of the relatively small sample size.
The Big Lung Trial differs from the other trials included in this summary in that it included some patients who had received preoperative induction chemotherapy (3%) and some who had undergone incomplete resections (6 to 15%). 14 The 381-patient trial used mainly second-generation chemotherapy agents and, like the ALPI trial, failed to detect a statistically significant survival benefit for preoperative or postoperative chemotherapy.
The International Adjuvant Lung Cancer Trial (IALT) is the largest RCT of adjuvant chemotherapy reported to date and was the first major trial to show a significant benefit to adjuvant chemotherapy in resected NSCLC. 15 To facilitate accrual, the following parameters were allowed to vary by center: disease stage, cisplatin dose, second chemotherapy agent (etoposide, vinorelbine, vinblastine, or vindesine), and use of radiotherapy after chemotherapy. After a median follow-up of 56 months, overall survival for the 1867 randomized patients was superior in the chemotherapy treatment arm, with a 4.1% absolute survival benefit at 5 years and a 14% relative reduction in the risk of death (hazard ratio [HR] 0.86; 95% CI, 0.76 -0.98; P Ͻ 0.03). The survival advantage observed with chemotherapy was maintained regardless of radiation (administered in 30% of study patients), choice of second drug (50% of patients received etoposide), dose of cisplatin, or disease stage. The third-generation vinca alkaloid combination vinorelbine/cisplatin regimen was used in only 26.8% of study patients.
ADJUVANT CHEMOTHERAPY AND RADIOTHERAPY
Three studies failed to show benefit from postoperative chemotherapy and radiotherapy compared with postoperative radiotherapy alone. The Lung Cancer Study Group 791 enrolled patients with incompletely resected NSCLC defined as either a positive resection margin or microscopic involvement by tumor in the highest lymph node sampled. 16 Patients received postoperative radiation followed by six cycles of CAP chemotherapy or observation alone. There was no difference in overall survival between the two groups.
In a French Cooperative Group trial, patients with completely resected stage I-III NSCLC were randomized to receive radiation alone or radiation followed by vincristine, lomustine, and CAP (COPAC) chemotherapy. The addition of chemotherapy did not result in any benefit compared with radiation alone. 17 Finally, in the most recent study, the Eastern Cooperative Oncology Group (ECOG) randomized 488 patients to postoperative adjuvant radiotherapy or the same radiotherapy administered concurrently with four cycles of etoposidecisplatin. 18 After a median follow-up of 44 months, survival was comparable for both treatment groups.
META-ANALYSES
The first definitive meta-analysis examining the efficacy of chemotherapy in NSCLC was published in 1995. 19 The analysis that compared curative surgery with or without chemotherapy included 14 trials (eight used cisplatin-based therapy) involving 4357 patients. This review included individual patient data and was conducted on an intent-to-treat basis. Across the five trials involving alkylating agents (n ϭ 2145), postoperative chemotherapy resulted in a statistically significant survival disadvantage. Compared with surgery alone, chemotherapy was associated with an absolute decrease in survival of 5% at 5 years and an overall relative increase in risk of death (HR 1.15; 95% CI, 1.04 -1.27; P ϭ 0.005).
However, for the eight trials involving adjuvant cisplatin-based regimens (n ϭ 1394 patients), chemotherapy was associated with a trend toward improved survival, with an absolute benefit of 5% at 5 years that corresponded to a 13% relative reduction in risk of death (HR 0.87; 95% CI, 0.74 -1.02; P ϭ 0.08).
In the analysis of surgery and radiotherapy with or without chemotherapy, there were seven trials (n ϭ 807 patients); six involved cisplatin-based chemotherapy. Chemotherapy was not associated with a significant survival benefit when all trials were included (HR 0.98; P ϭ 0.76) or for the six cisplatin-based trials (HR 0.94; 95% CI, 0.79 -1.11; P ϭ 0.46).
Several subsequent review articles and meta-analyses have also confirmed the value of adjuvant cisplatin-based and UFT-based chemotherapy for NSCLC. 19 -25 These analyses have reported HRs ranging from 0.74 at 7 years for adjuvant UFT 22 to 0.89 overall for cisplatin-based chemotherapy 24, 25 with absolute improvements in survival at 5 years of approximately 5%.
In summary, although most of the early chemotherapy trials did not show a significant survival benefit in resected NSCLC, a signal of potential benefit emerged even in some of the trials performed in the CAP era. It is clear now that the small trials performed in the 1970s and 1980s were severely underpowered, with none of them having a sample size that would be adequate to confirm a modest but potentially clinically meaningful survival benefit. This was true even for the first meta-analysis that demonstrated a 5% absolute survival benefit at 5 years, yet the difference was not significant. 3 In contrast, in the IALT trial that had almost 2000 patients, there was a significant difference in overall survival (HR 0.86; P Ͻ 0.03) and a 4.1% absolute improvement in 5-year survival. However, the use of adjuvant chemotherapy was not widely adopted despite the significant results of IALT. This may be attributed to the negative results of the ALPI, Big Lung Trial, and ECOG studies 12, 14, 18 and because many oncologists and patients thought that the degree of treatment-related toxicity outweighed the potential 5% gain in overall survival.
MODERN CHEMOTHERAPY REGIMENS
The results of two North American Cooperative Group trials 4, 5 were presented at the 2004 annual meeting of the American Society of Clinical Oncology. The dramatic results from these studies led to the widespread adoption of adjuvant chemotherapy for resected NSCLC. These studies, together with the recently presented European Cooperative trial, 6 are reviewed in detail in this section. Important study characteristics are presented in Table 2 .
The Cancer and Leukemia Group B trial (CALGB 9633) 4 randomized patients with resected stage IB (T2N0M0) tumors to four cycles of adjuvant paclitaxel (200 mg/m 2 ) and carboplatin (AUC 6 mg/mL x min) over 12 weeks versus observation alone. The study was stopped prematurely by the data and safety monitoring board after enrolling 344 of a planned 384 patients. The treatment was well tolerated with no chemotherapy-related toxic deaths, and the most common grade 3/4 toxicity was neutropenia (36%). Compliance with all four cycles of treatment was also good; 85% of randomized patients received four cycles of chemotherapy. Despite the relatively short median follow-up of only 34 months, a statistically significant survival advantage was detected for adjuvant chemotherapy with an absolute benefit of 12% at 4 years (71% versus 59%; P ϭ 0.028). A multivariate analysis adjusting for important prognostic variables (including age, gender, tumor size, and presence of symptoms) confirmed a significant reduction in the risk of death from lung cancer with adjuvant chemotherapy (Cox model: HR 0.62; 95% CI, 0.40 -0.97; P ϭ 0.034). Lung cancer-specific mortality was also significantly reduced with the use of chemotherapy (HR 0.51; 95% CI, 0.29 -0.89; P ϭ 0.018).
The results of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) North American intergroup study JBR.10 were also presented at the ASCO 2004 meeting and published in full in 2005. 5 In this study, 482 patients with completely resected stages IB and II (excluding T3N0) tumors were randomized to receive four cycles of adjuvant vinorelbine (25 mg/m 2 weekly) and cisplatin (50 mg/m 2 days 1 and 8) over 16 weeks or observation alone. Postoperative radiotherapy was not permitted in either CALGB 9633 or JBR.10.
The JBR.10 study regimen was associated with significantly more hematological toxicity than CALGB 9633, and there were two treatment-related deaths. Grade 3/4 neutropenia was seen in 73% of patients, and only 45% of randomized patients completed four cycles of therapy. The incidence of febrile neutropenia was 7% in the treatment arm. However, other than fatigue (15%), grade 3/4 toxicity rates were uncommon (Ͻ10%). Despite these toxicities, patients who received adjuvant chemotherapy reported only modest impairment of their quality of life while on treatment, and quality of life improved within the first year after surgery. 26 After a median follow-up of 5.1 years, overall survival strongly favored the adjuvant chemotherapy arm with an absolute survival benefit of 15% at 5 years (69% versus 54%) and a 30% relative reduction in the risk of death (P ϭ 0.012). Subgroup analysis demonstrated no statistically significant benefit from adjuvant chemotherapy in the patients with stage IB disease (survival benefit at 5 years 7%; P ϭ not significant). However, because of smaller numbers (45% of study participants), lower than expected events rates in this sub- group, and the lack of a statistically significant stage-bytreatment interaction, the authors concluded that adjuvant vinorelbine and cisplatin should become standard of care for patients with both stage IB and II completely resected NSCLC.
The most recent trial to be presented is the Adjuvant Navelbine International Trialists Association (ANITA) study. 6 This cooperative European study randomized patients with resected stages IB, II, and IIIA NSCLC to receive four cycles of vinorelbine (30 mg/m 2 weekly) and cisplatin (100 mg/m 2 every 4 weeks) over 16 weeks or observation alone. The use of radiotherapy was at the discretion of participating centers. Unlike the previous two studies in which only patients with ECOG performance status 0-1 were eligible, this study included patients with poorer performance status (ECOG 0-2). The study groups were equal at baseline with respect to important prognostic factors, and both study arms showed approximately even proportions of the various stages of disease. More patients in the observation arm received postoperative radiotherapy compared with those in the chemotherapy arm (approximately 30% versus 20%).
Toxicity in the ANITA trial was greater than that in JBR.10. Grade 3/4 neutropenia was seen in 85% of patients, and febrile neutropenia occurred in 12.5% of treated patients. There were six toxic deaths in the treatment group. Rates of grade 3/4 infection, anemia, nausea/vomiting, anorexia, and asthenia were all Ͼ10% in this trial. The median relative dose intensity was 58.6% and 88.9% for vinorelbine and cisplatin, respectively.
Despite the added toxicity, after a median follow-up of Ͼ70 months, overall survival (65.8 versus 43.8 months), 2-year survival (67.9% and 62.8%), and 5-year survival (51.2% versus 42.6%) were significantly improved with adjuvant therapy. Subgroup analysis suggested that patients with stage IB disease did not benefit significantly from adjuvant chemotherapy. A further finding of subgroup analysis was that patients with resected stage IIIA disease derived significant benefit from postoperative radiotherapy. The authors concluded that adjuvant vinorelbine and cisplatin should be considered the standard of care for patients with resected stage II and IIIA NSCLC.
UFT-BASED CHEMOTHERAPY Oral Agents Alone or in Combination with Other Chemotherapy Agents
In Japan, the oral antimetabolite UFT either alone or combined with other intravenous agents has been evaluated in several studies (Table 3 ). In the largest fully published trial, Kato et al. 36 administered UFT postoperatively for 2 years to patients with resected stage I NSCLC. The study included 976 patients and reported a statistically significant survival benefit in favor of UFT administration (HR 0.71; 95% CI, 0.52-0.98). However, in a smaller RCT of patients with stage I and II NSCLC, Endo et al. 35 did not find a survival benefit associated with adjuvant UFT monotherapy compared with observation alone.
Other investigators have assessed the combination of UFT with intravenous chemotherapy. Wada et al. 31 performed a three-armed study in which 310 patients with resected stages I-III NSCLC were randomized to observation, 1 year of UFT alone, or three cycles of vindesine/cisplatin followed by 1 year of UFT. Although survival was significantly improved with UFT alone, the combination of UFT with intravenous chemotherapy did not confer a statistically significant survival benefit. However, a similar three-armed study involving only 150 patients with stage I disease showed conflicting results. Imaizumi et al. 37 reported that the combination of vindesine/cisplatin (two cycles) and UFT (2 years) was associated with significantly improved overall survival compared with observation, whereas there was no significant difference in outcome with UFT alone.
In a meta-analysis of UFT chemotherapy 22 that pooled individual patient data from six RCTs (n ϭ 2003 patients, 96% stage I disease), survival rates at 5 and 7 years were significantly higher in the surgery plus UFT group (81.5% and 76.5%) than in the surgery-alone group (77.2% and 69.5%, respectively; P ϭ 0.011 and P ϭ 0.001, respectively).
DISCUSSION AND CONCLUSION
Although meta-analyses and some early RCTs suggested a potential benefit to adjuvant chemotherapy for resected NSCLC in the 1990s, it was not until the publication of three recent landmark studies that adjuvant chemotherapy was fully established as the standard of care. Questions that remain unanswered are: which patients should be treated, at what stage of disease, and with which chemotherapy regimen?
Whereas the JBR.10 and ANITA trials (in preplanned subset analyses) did not show a significant benefit for patients with stage IB disease, the CALBG study, which enrolled only patients with stage IB disease, showed a clear benefit. 4 -6 However, the follow-up of this trial is not yet mature, and the survival curves as presented suggest that the absolute benefit at 5 years will be less than 10%. At this time, thoracic surgeons and medical oncologists should keep an open mind, and individual treatment decisions should be reached after an assessment of patient suitability for chemotherapy and after a full discussion of the individual trial results with each patient. The use of oral UFT has shown activity in Japanese studies, particularly in those with stage I adenocarcinomas. However, this regimen remains untested in the western world and, because of potential pharmacogenomic differences, its clinical use should be restricted to the patient population in which it has been studied. The results of the JBR.10 and ANITA studies clearly and unequivocally demonstrate that patients with stage II and IIIA NSCLC benefit from adjuvant vinorelbine and cisplatin, and this or similar treatment should be offered to fit patients able to tolerate therapy.
In the advanced disease setting, all platinum-based doublet chemotherapy combinations incorporating vinorelbine, gemcitabine, and the taxanes paclitaxel and docetaxel have demonstrated similar activity and efficacy. 38 Therefore, it is reasonable to conclude that these regimens should have similar efficacy in the adjuvant setting. For that reason, some oncologists have elected to use as adjuvant therapy the regimen used most frequently in their centers for advanced stage IV NSCLC. Although such a decision is clearly not evidence-based, it does not seem unreasonable, and the familiarity and comfort level that staff develop with the frequent usage of a small number of regimens may allow for better patient support and education and, potentially, even to lower rates of toxicity. The dosing schedules used in both the JBR.10 and ANITA trials were associated with substantial hematological toxicity. Because of this toxicity and the low rate of drug delivery in these trials, many clinicians have modified the treatment schedules into a better tolerated 21-day cycle with vinorelbine 25-30 mg/m 2 on days 1 and 8 and cisplatin 75-80 mg/m 2 on day 1. However, it is important to recognize that this regimen is not the schedule used in either clinical trial and that the impressive survival benefit in both JBR.10 and ANITA was seen despite the relatively high rates of hematological toxicity and low dose delivery. Furthermore, a recent analysis of three trials of chemotherapy for advanced NSCLC found the presence of neutropenia to be associated with increased survival. This suggests that hematological toxicity may be a biological marker of drug activity and its absence may potentially reflect underdosing. 39 The selection of patients appropriate for adjuvant therapy depends largely on performance status and accompanying co-morbid conditions. Whereas the CALGB and JBR.10 studies enrolled only patients with ECOG performance status 0-1, the ANITA trial also included patients with ECOG performance status 2. It is also important to note that median patient age in these studies was 59-61 years, whereas the median age of all patients diagnosed with NSCLC is older than 70 years. Treatment of the elderly patient with lung cancer is a frequently debated topic. Most recent opinions suggest that physiologic (not chronologic) age should dictate which patients are most appropriate for therapy. 40, 41 In the less robust elderly patient for whom platinum-based therapy may not be appropriate, single-agent treatment has been shown to prolong survival in the advanced setting. 42 Whether this may extend to the adjuvant setting would require prospectively designed trials.
Despite the major therapeutic advances in adjuvant chemotherapy for resected NSCLC achieved in the past few years, a significant proportion of patients will ultimately relapse and die from their disease. The addition of molecularly targeted agents to chemotherapy in the adjuvant setting seems to be a logical next step in view of their recently demonstrated benefit in the advanced disease setting. 43, 44 Indeed, a North American intergroup trial that compared adjuvant gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to placebo was initiated. However, a recently presented study of maintenance gefitinib versus observation alone after concurrent chemotherapy and radiation for unresectable stage III NSCLC suggested a nonsignificant survival disadvantage to the use of gefitinib. 45 Therefore, the intergroup study of adjuvant gefitinib was closed prematurely after the accrual of only 502 patients, and all patients were taken off study drug. A similar trial with the EGFR inhibitor erlotinib is being planned because this agent has been shown to prolong the survival of patients with advanced NSCLC after first-line or second-line chemotherapy. 43 A large ECOG randomized trial of chemotherapy with paclitaxel/carboplatin plus or minus bevacizumab in patients with advanced non-squamous cell lung cancer was reported recently by Sandler et al. 45 at the 2005 ASCO meeting. The significant survival benefit seen in this study prompted the development of a North American intergroup trial of chemotherapy plus or minus bevacizumab as adjuvant therapy after complete resection of stages IB to IIIA NSCLC; this study is scheduled to open shortly.
In summary, the role of adjuvant chemotherapy is now clearly established in patients with resected NSCLC. Future studies are needed to clarify the roles of various chemotherapy combinations and the ideal dosing schedule and to determine which subgroups of patients derive the most benefit from treatment. However, despite significant advances in treatment, mortality from lung cancer remains high, and preventing this disease through global public health tobacco reduction programs is of paramount importance.
